Pharsight

Levothyroxine Sodium patents expiration

LEVOTHYROXINE SODIUM IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168238 FRESENIUS KABI USA Levothyroxine formulations
Aug, 2032

(8 years from now)

US9168239 FRESENIUS KABI USA Levothyroxine formulations
Aug, 2032

(8 years from now)

US9006289 FRESENIUS KABI USA Levothyroxine formulations
Oct, 2032

(8 years from now)

US11135190 FRESENIUS KABI USA Levothyroxine liquid formulations
Dec, 2036

(12 years from now)

US9782376 FRESENIUS KABI USA Levothyroxine liquid formulations
Dec, 2036

(12 years from now)

US10398669 FRESENIUS KABI USA Levothyroxine liquid formulations
Dec, 2036

(12 years from now)

Levothyroxine Sodium is owned by Fresenius Kabi Usa.

Levothyroxine Sodium contains Levothyroxine Sodium.

Levothyroxine Sodium has a total of 6 drug patents out of which 0 drug patents have expired.

Levothyroxine Sodium was authorised for market use on 24 June, 2011.

Levothyroxine Sodium is available in solution;intravenous, powder;intravenous dosage forms.

The generics of Levothyroxine Sodium are possible to be released after 01 December, 2036.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 24 June, 2011

Treatment: NA

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

How can I launch a generic of LEVOTHYROXINE SODIUM before it's drug patent expiration?
More Information on Dosage

LEVOTHYROXINE SODIUM family patents

Family Patents
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154498 HIKMA Stabilized liquid formulation of levothyroxine
Jul, 2036

(12 years from now)

Levothyroxine Sodium is owned by Hikma.

Levothyroxine Sodium contains Levothyroxine Sodium.

Levothyroxine Sodium has a total of 1 drug patent out of which 0 drug patents have expired.

Levothyroxine Sodium was authorised for market use on 17 May, 2021.

Levothyroxine Sodium is available in solution;intravenous dosage forms.

The generics of Levothyroxine Sodium are possible to be released after 20 July, 2036.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 17 May, 2021

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of LEVOTHYROXINE SODIUM before it's drug patent expiration?
More Information on Dosage

LEVOTHYROXINE SODIUM family patents

Family Patents